More results from Phase 1 study
Results of the evaluation of PSA values have been reported in the clinical phase 1 study that SpectraCure is currently running for treatment of patients with recurrent prostate cancer, using the company's photodynamic therapy (PDT) method. PSA (prostate-specific antigen) is a blood marker that can indicate the presence of a tumour in the prostate.
The most recently treated patients had PSA values of 4.7 ng/ml and 5.7 ng/ml, respectively, prior to treatment. One month after treatment, the values had decreased to 0.3 ng/ml and 3.5 ng/ml, respectively.
SpectraCure has previously reported that MR images of the prostate taken one week after treatment showed a clear destruction of the tumour area, which is the intended effect of the PDT treatment.
It should be emphasized that the main objective of the Phase 1 study is to show that SpectraCure's treatment method is safe, and to determine the correct dose level. The preliminary results also suggest that the method has the intended effect, which is a secondary objective for the phase 1 study.
For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: firstname.lastname@example.org, phone: +46-(8)-503 000 50.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region